Skip to main content
. 2009 Feb 10;4(2):e4420. doi: 10.1371/journal.pone.0004420

Figure 1. Treatment Schema.

Figure 1

Subjects were treated with EPOCH chemotherapy for cycles 1 and 2 and then responses assessed. Patients with complete remissions (CR) or partial remissions (PR), received cycles 3 and 4, whereas patients with stable disease received antiviral therapy. Similar treatment assignments were applicable after cycles 3 and 4, with patients in CR or PR receiving cycles 5 and 6 EPOCH therapy, except for one patient who was in CR after cycles and 1 and 2, and remained in CR after cycles 3 and 4, and one patient in PR after cycles 1 and 2 and achieved “best response”, i.e. PR after cycles 3 and 4, who then received antiviral therapy. Subjects with stable disease, PR, or CR after 6 cycles of therapy then received antiviral therapy. Subjects with disease progression or toxicity during any stage of treatment, were taken off the treatment protocol, and were eligible to receive non-protocol therapies.